About usPharmidex was created in 2002 to provide unique expertise to clients who were developing medicines for CNS diseases.
Since then, Pharmidex has established itself as the world leading centre for studying CNS drug distribution and biochemical responses to new drugs using its proprietary NeuroPK® and NeuroPD® technologies. Using these technologies drug action can be associated with free drug levels at the target site and systemic pharmacokinetic data.
Clients can therefore progress their compounds based-on high quality, translational scientific data which can be much more closely linked to clinical outcomes and likely clinical success.
We focus on the key data, decision-points and milestones that allow our clients to make the best decisions possible for their programmes and portfolio.
Pharmidex prides itself on:
- Customer care and satisfaction
- Flexible and broad range of study options
- High quality data
- Fast turnaround times
- Value for money
Today Pharmidex provides an extensive range of in vitro, in situ and in vivo ADMET/PK technologies covering a wide range of species, to underpin its world leading CNS expertise.
Clients can select from the extensive platform technologies or request bespoke studies to address specific needs, all of which are rapidly undertaken by highly qualified scientists from academic and industry backgrounds.
Scientists and Management Team at Pharmidex have extensive knowledge of discovery and development of new drugs covering a broad range of drug target.
Pharmidex has its own research activities which include providing clients with better ways to deliver drugs to the brain called Cerense this technology can improve the brain uptake of both large (macromolecules) and small, new or existing drugs offering better efficacy, less side-effects or just delivering therapies that could never access the brain.
Pharmidex has a very successful track record in obtaining financial support for our scientific development via grant applications in the US, UK and EU and by partnering on a 'shared risk-shared gain' basis with other companies. This proven approach has led to the co-development of the CNS delivery system, Cerense with Genzyme Pharmaceuticals.